Filed - Glenmark

More documents

Recommendations

Info

Latin America Going forward Expand presence in Oncology to other Latin American markets as well as other key less regulated markets: use Argentina as the hub File an additional 10 dossiers in markets across Latin America in the second half of the year. Launch 10 new products in Brazil Margin expansion through increasing revenue for products filed from Indian parent Divisionalisation for greater focus – focus on high margin segments Achieve 100% growth in revenues over FY 2006 Expect to Meet Guidance for FY07 19
Less Regulated Markets Current Status (Apr-Sep 06) Plan going forward… Posted 96% growth in revenues fuelled by growth in Russia and acquisitions in South Africa Registered products in 2 new countries and started operations in 4 Consolidate position in Russia Expand in South Africa – use the India advantage to file several products Focus on high potential country markets Completed 249 filings and received 137 approvals for products across markets Diversify portfolio to include an oncology line – leverage the acquisition of Servycal in Argentina Consolidated position in existing markets: increased field force, launched many new products, reviewed portfolio to meet local requirements Continue registration of products across geographies Achieve over 40% growth in revenues over FY 2006 Evaluate acquisition candidates in highpotential RoW markets Expect to Meet Guidance for FY07 20
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History 29-year old com
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Research and Development 5
Page 10 and 11: Licensing Strategy Partner Selectio
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: NCE Pipeline Lead Target Indication
Page 16 and 17: Generic Formulations 13
Page 18 and 19: USA - Generic Formulations Current
Page 20 and 21: Europe - Start-up phase Strategy &
Page 24 and 25: India Formulations Current Status
Page 26 and 27: India Formulations Moving forward,
Page 28 and 29: Active Pharmaceutical Ingredients C
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Financials and Projections Mileston
Page 34 and 35: Summary 31
Page 36: Thank you 33

Filed - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?